We showed that the age, presence of pneumonia, dementia, fever, dyspnea, and food rejection are independent risk factors for mortality from COVID-19 in nursing homes, and that periodic screening is key for transmission control in this setting. We described a higher risk of adverse reactions after mRNA-1273 compared to BNT162b2 ,and higher after second dose (vs first) for both vaccines in 2.300 healthcare personnel. We have co-coordinated a multicentre phase 2 trial to evaluate immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants and have participated in three large phase III trials on COVID-19 vaccines for general population (Ad26.COV2.S and COVID-19 HIPRA) and in pregnancy (BNT162b2). We are also part EU consortiums to monitor to assess brand-specific COVID-19 (COVIDRIVE) and influenza (DRIVE) vaccine effectiveness. We have led the first national consensus on vaccination in Multiple Sclerosis patients who are candidate to immunosuppressive therapies.
Group Leader
Magda Campins Martí
Principal Investigator (PI)
Lluis Armadans Gil, Magda Campins Martí, Xavier Martinez Gómez, Susana Otero Romero
Researchers
Valentina Balasso, Blanca Borrás Bermejo, César Llorente Parrado, José María Sanchez García, Oleguer Parés Badell, Jose Ángel Rodrigo Pendás, Sonia Uriona Tuma
PhD Students
Ricardo Zules Oña, Irene Torrecilla Martínez, Mar Forneguera Padros, Arnau Peñalver Piñol, Martí Vivet Escale
Nursing and Technical Staff
Laia Pinós Tella, Elisa Navarro Royo, Carmen Ferrer Barbera, Cristian Quintana Alonso, Agustín Gayubas Jurado, Daniel Dorado Alvarez, Silvia Aneas Posadas, Eva del Amo Moran, Ingrid Carbones Fargas, Cristina Ferrer Pujol, Constanza Olivares Castillo.
26
PUBLICATIONS
186
IMPACT FACTOR
7.17
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Parés-Badell O, Martínez-Gómez X, Pinós L, Borras-Bermejo B, Uriona S, Otero-Romero S, Rodrigo-Pendás JÁ, Cossio-Gil Y, Agustí A, Aguilera C, Campins M.
Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection.
Vaccines (Basel). 2021 Dec 10;9(12):1463
DOI: doi: 10.3390/vaccines9121463.
IF: 4.42
Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J,
Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea
M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet. 2021 Jul 10;398(10295):121-130
DOI: doi: 10.1016/S0140-6736(21)01420-3
IF: 79.32
Suescún-Carrero SH, Salamanca-Cardozo LP, Pinazo MJ, Armadans-Gil L.
Sensitivity and Specificity of two rapid tests for the diagnosis of infection by Trypanosoma cruzi in a Colombian population
PLoS Negl Trop Dis. 2021 Jun 2;15(6):e0009483
DOI: doi: 10.1371/journal.pntd.0009483
IF: 4.41
Otero-Romero S, Ascherio A, Lebrun-Frénay C
Vaccinations in multiple sclerosis patients receiving disease-modifying drugs.
Curr Opin Neurol. 2021 Jun 1;34(3):322-328
DOI: doi: 10.1097/WCO.0000000000000929
IF: 5.71
Meis-Pinheiro U, Lopez-Segui F, Walsh S, Ussi A, Santaeugenia S, Garcia-Navarro JA, San-Jose A, Andreu AL, Campins M, Almirante B.
Clinical characteristics of COVID-19 in older adults. A retrospective study in long-term nursing homes in Catalonia.
PLoS One. 2021 Jul 23;16(7):e0255141
DOI: doi: 10.1371/journal.pone.0255141
IF: 3.24
Estudio de comorbilidad y de inmunogenicidad vacunal en una cohorte prospectiva de pacientes con primeros brotes sugestivos de Esclerosis Múltiple
Principal Investigator: Otero Romero, Susana
Agency: Instituto de Salud Carlos III (PI19/01606)
Funding: 105,270€
Period: 2020 – 2022
Measuring brand-specific influenza vaccine effectiveness (DRIVE)
Principal Investigator: Campins Martí, Magda
Agency: The Innovative Medicines Initiative (DRIVE_IMI2-2020_SUBART11)
Funding: 75,438€
Period: 2020 – 2021
BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS)
Principal Investigator: Campins Martí, Magda
Agency: Instituto Carlos III
Funding: None
Period: 2021 – 2022
Immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) againts SARS-COV-2 in adults fully vaccinated againts COVID-19
Principal Investigator: Otero Romero, Susana
Agency: HIPRA
Funding: 225,000€
Period: 2021-2022
Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 (ENSEMBLE 2)
Principal Investigator: Otero Romero, Susana
Agency: Janssen Vaccines & Prevention
Funding: 350,000€
Period: 2020-2022
